SCHEMBL5651979

SCHEMBL5651979

O=C(NCCCN1CCN(c2cccc(Cl)c2)CC1)c1ccc(-c2nc3ncccc3[nH]2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 5/20 0.57
DRD2 P14416 3/20 0.57
ADRA1A P35348 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.55
USP2 O75604 1/20 0.55
ALDH1A1 P00352 1/20 0.55
GSK3B P49841 2/20 0.55
TSHR P16473 1/20 0.55
KCNH2 Q12809 2/20 0.53
HTR2A P28223 2/20 0.53
HTR1A P08908 1/20 0.53
ADRA2A P08913 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53
ADRA1D P25100 1/20 0.53
HRH1 P35367 1/20 0.53
ADRA1B P35368 1/20 0.53
MAPT P10636 4/20 0.53
LMNA P02545 2/20 0.53
TP53 P04637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652469 0.88 DRD3 (0.58) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL5649243 0.87 DRD3 (0.57) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL5649853 0.85 DRD3 (0.59) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL5651142 0.85 DRD3 (0.66) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL5652458 0.81 DRD3 (0.58) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL5650883 0.81 DRD3 (0.60) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL5650872 0.81 DRD3 (0.60) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL5649253 0.81 HTR2A (0.58) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL5650125 0.78 DRD2 (0.60) DRD3DRD2ADRA1ASMN1; SMN2USP2
SCHEMBL7438237 0.73 DRD3 (1.00) DRD3DRD2ADRA1AKCNH2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 DRD3 3697/4885DRD2 3803/4885ADRA1A 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.